178 related articles for article (PubMed ID: 38861041)
1. Breast cancer epigenetics: current and evolving treatment.
Purja S; Nguyen DT; Kim E
Breast Cancer; 2024 Jun; ():. PubMed ID: 38861041
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
[TBL] [Abstract][Full Text] [Related]
4. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond.
Feng J; Meng X
Front Pharmacol; 2022; 13():946811. PubMed ID: 36188615
[TBL] [Abstract][Full Text] [Related]
5. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
6. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
Singh D; Khan MA; Siddique HR
Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
[TBL] [Abstract][Full Text] [Related]
7. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Kreutzfeldt J; Rozeboom B; Dey N; De P
Am J Cancer Res; 2020; 10(4):1045-1067. PubMed ID: 32368385
[TBL] [Abstract][Full Text] [Related]
8. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S; Harper-Wynne C; Park YH; Franke F; de Laurentiis M; Schumacher-Wulf E; Eiger D; Heeson S; Cardona A; Özyilkan Ö; Morales-Vàsquez F; Metcalfe C; Hafner M; Restuccia E; O'Shaughnessy J
BMC Cancer; 2024 May; 24(1):641. PubMed ID: 38789924
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer.
Wang J; Zhang Q; Li Q; Mu Y; Jing J; Li H; Li W; Wang J; Yu G; Wang X; Ouyang Q; Hao J; Lu L; Zhou L; Guan J; Li Q; Xu B
Target Oncol; 2021 Sep; 16(5):591-599. PubMed ID: 34196874
[TBL] [Abstract][Full Text] [Related]
10. Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Andrahennadi S; Sami A; Manna M; Pauls M; Ahmed S
Curr Oncol; 2021 May; 28(3):1803-1822. PubMed ID: 34064867
[No Abstract] [Full Text] [Related]
11. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
Masuda N; Tamura K; Yasojima H; Shimomura A; Sawaki M; Lee MJ; Yuno A; Trepel J; Kimura R; Nishimura Y; Saji S; Iwata H
BMC Cancer; 2021 Nov; 21(1):1269. PubMed ID: 34819039
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights.
Suo J; Zhu K; Zhuang C; Zhong X; Bravaccini S; Maltoni R; Bertucci F; Zheng H; Luo T
Ann Transl Med; 2023 Dec; 11(12):409. PubMed ID: 38213803
[TBL] [Abstract][Full Text] [Related]
14. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
Schettini F; Buono G; Cardalesi C; Desideri I; De Placido S; Del Mastro L
Cancer Treat Rev; 2016 May; 46():20-6. PubMed ID: 27057657
[TBL] [Abstract][Full Text] [Related]
15. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
16. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.
Thanopoulou E; Khader L; Caira M; Wardley A; Ettl J; Miglietta F; Neven P; Guarneri V
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182657
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives.
Buocikova V; Rios-Mondragon I; Pilalis E; Chatziioannou A; Miklikova S; Mego M; Pajuste K; Rucins M; Yamani NE; Longhin EM; Sobolev A; Freixanet M; Puntes V; Plotniece A; Dusinska M; Cimpan MR; Gabelova A; Smolkova B
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287297
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Iwata H; Nakamura R; Masuda N; Yamashita T; Yamamoto Y; Kobayashi K; Tsurutani J; Iwasa T; Yonemori K; Tamura K; Aruga T; Tokunaga E; Kaneko K; Lee MJ; Yuno A; Kawabata A; Seike T; Kaneda A; Nishimura Y; Trepel JB; Saji S
Jpn J Clin Oncol; 2023 Jan; 53(1):4-15. PubMed ID: 36398439
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
